Elaia Fuels Europe's Deep Tech Future with €134M Fund
March 14, 2026, 3:31 am
Location: France, Ile-de-France, Le Chesnay-Rocquencourt
Employees: 1001-5000
Founded date: 1967
Elaia has closed its €134 million DTS3 fund. This deep tech seed fund targets European B2B startups. It doubles prior deep tech allocations. Elaia partners with top research institutions. The fund invests €1M-€13M in early-stage ventures. Focus areas include computing, industry, and life sciences. This drives innovation across Europe.
Elaia secures substantial capital. Its third Deep Tech Seed fund, DTS3, is now closed. The fund reached €134 million. This marks a significant milestone. It doubles the size of Elaia's previous deep tech seed funds. This capital injection targets Europe's burgeoning innovation landscape. The firm solidifies its position. Elaia stands as a leading European deep tech investor.
DTS3 emphasizes early-stage investment. It focuses on pre-seed and seed-stage B2B startups. Investment checks range from €1 million to €13 million. This strategic approach backs founders at their earliest stages. It provides critical funding. This supports the development of breakthrough technologies. These technologies address fundamental bottlenecks across various sectors.
The fund's strategy rests on strong partnerships. Elaia collaborates with elite European research institutions. These include PSL, INRIA, CNRS, the Barcelona Supercomputing Centre, and the Max Planck Foundation. This model provides early access. It grants visibility into cutting-edge technologies. It also identifies exceptional founding teams. This partnership approach has proven effective. Previous funds like the PSL Innovation Fund and Elaia Alpha II Fund demonstrated success. They produced companies like Aqemia, Alice&Bob, and Mablink Bioscience. Mablink Bioscience was acquired by Eli Lilly.
Elaia sees rapid innovation across Europe. The firm notes an accelerating pace. European deep tech shows "escape velocity." This trend rivals any global ecosystem. Innovation hubs emerge continent-wide. From Zurich to Paris, new centers of excellence arise. DTS3's deployment spans multiple European markets. These include France, Germany, Spain, the UK, and Switzerland. This demonstrates an international ambition.
The DTS3 fund has already made significant investments. Since its initial €60 million close in March 2024, it has deployed capital into 11 portfolio companies. These ventures span computing, life sciences, and industrial innovation. Specific examples highlight the fund's diverse focus.
Proxima Fusion, based in Germany, is one key investment. It develops stellarator-based fusion power plants. This aims to provide clean, safe, and limitless baseload energy. Its goal is to position Europe as a leader in commercial fusion by the 2030s. This represents a monumental leap in energy technology.
Another portfolio company is France's GetVocal. This firm develops fully auditable conversational AI agents. These agents enhance enterprise customer support. They enable companies to build trustworthy human-AI workforces. Real-time oversight and transparent governance are core features. This advances the future of customer experience.
Biophta, also from France, focuses on life sciences. It offers a topical ophthalmic insert. This innovative solution replaces daily eye drops and invasive injections. It addresses conditions like glaucoma and macular edema. The solution is simple and patient-friendly. It revolutionizes ophthalmic care.
DTS3's investment strategy is structured around three core pillars. These define the future of technology and human well-being. The first pillar is the future of computing. This encompasses artificial intelligence, cybersecurity solutions, advanced semiconductors and photonics, and quantum computing. These areas are vital for next-generation digital infrastructure.
The second pillar targets the future of industry. It includes physical AI applications, advanced robotics, new material science, and sustainable energy solutions. These investments aim to transform manufacturing, logistics, and resource management. They drive efficiency and sustainability.
The third pillar focuses on the future of life sciences. This broad category covers biotechnology advancements, digital health platforms, and innovative medical devices. These investments promise to redefine healthcare delivery, diagnostics, and therapeutics. They improve global health outcomes.
Elaia, founded in 2002, boasts a deep history. It is a European full-stack tech and deep tech investor. The firm manages €1 billion in assets. It has partnered with over 100 startups. Its track record includes notable names. Criteo, Mirakl, Shift Technology are among its successes. Alice & Bob, Aqemia, Vibe, and iBanFirst also feature. This robust history underscores its expertise.
Beyond DTS3, Elaia continues its expansive investment strategy. Earlier this year, in February, Elaia announced the first close of its fifth Digital Venture Fund (DV5). This fund secured €120 million. It aims to scale to €300 million. This demonstrates Elaia's continuous commitment. It invests across various stages and technological domains.
Elaia's network extends across Europe. It maintains offices in Paris, Barcelona, and Tel Aviv. This geographic presence supports its pan-European investment mandate. It fosters strong ties with local ecosystems. The firm operates a joint venture with Lazard, Lazard Elaia Capital. This partnership further supports founders. It provides resources at any stage of their growth.
DTS3 reflects Elaia's unwavering international ambition. It backs founders across the entire European continent. Its growing investor network mirrors this geographic diversity. Elaia is currently in an intense deployment phase. The firm actively seeks ambitious entrepreneurs. These visionaries are building Europe's next generation of deep tech companies. This fund will drive significant innovation. It shapes Europe's technological leadership. It fosters economic growth and solves critical global challenges. Elaia stands ready. It empowers the innovators of tomorrow.
Elaia secures substantial capital. Its third Deep Tech Seed fund, DTS3, is now closed. The fund reached €134 million. This marks a significant milestone. It doubles the size of Elaia's previous deep tech seed funds. This capital injection targets Europe's burgeoning innovation landscape. The firm solidifies its position. Elaia stands as a leading European deep tech investor.
DTS3 emphasizes early-stage investment. It focuses on pre-seed and seed-stage B2B startups. Investment checks range from €1 million to €13 million. This strategic approach backs founders at their earliest stages. It provides critical funding. This supports the development of breakthrough technologies. These technologies address fundamental bottlenecks across various sectors.
The fund's strategy rests on strong partnerships. Elaia collaborates with elite European research institutions. These include PSL, INRIA, CNRS, the Barcelona Supercomputing Centre, and the Max Planck Foundation. This model provides early access. It grants visibility into cutting-edge technologies. It also identifies exceptional founding teams. This partnership approach has proven effective. Previous funds like the PSL Innovation Fund and Elaia Alpha II Fund demonstrated success. They produced companies like Aqemia, Alice&Bob, and Mablink Bioscience. Mablink Bioscience was acquired by Eli Lilly.
Elaia sees rapid innovation across Europe. The firm notes an accelerating pace. European deep tech shows "escape velocity." This trend rivals any global ecosystem. Innovation hubs emerge continent-wide. From Zurich to Paris, new centers of excellence arise. DTS3's deployment spans multiple European markets. These include France, Germany, Spain, the UK, and Switzerland. This demonstrates an international ambition.
The DTS3 fund has already made significant investments. Since its initial €60 million close in March 2024, it has deployed capital into 11 portfolio companies. These ventures span computing, life sciences, and industrial innovation. Specific examples highlight the fund's diverse focus.
Proxima Fusion, based in Germany, is one key investment. It develops stellarator-based fusion power plants. This aims to provide clean, safe, and limitless baseload energy. Its goal is to position Europe as a leader in commercial fusion by the 2030s. This represents a monumental leap in energy technology.
Another portfolio company is France's GetVocal. This firm develops fully auditable conversational AI agents. These agents enhance enterprise customer support. They enable companies to build trustworthy human-AI workforces. Real-time oversight and transparent governance are core features. This advances the future of customer experience.
Biophta, also from France, focuses on life sciences. It offers a topical ophthalmic insert. This innovative solution replaces daily eye drops and invasive injections. It addresses conditions like glaucoma and macular edema. The solution is simple and patient-friendly. It revolutionizes ophthalmic care.
DTS3's investment strategy is structured around three core pillars. These define the future of technology and human well-being. The first pillar is the future of computing. This encompasses artificial intelligence, cybersecurity solutions, advanced semiconductors and photonics, and quantum computing. These areas are vital for next-generation digital infrastructure.
The second pillar targets the future of industry. It includes physical AI applications, advanced robotics, new material science, and sustainable energy solutions. These investments aim to transform manufacturing, logistics, and resource management. They drive efficiency and sustainability.
The third pillar focuses on the future of life sciences. This broad category covers biotechnology advancements, digital health platforms, and innovative medical devices. These investments promise to redefine healthcare delivery, diagnostics, and therapeutics. They improve global health outcomes.
Elaia, founded in 2002, boasts a deep history. It is a European full-stack tech and deep tech investor. The firm manages €1 billion in assets. It has partnered with over 100 startups. Its track record includes notable names. Criteo, Mirakl, Shift Technology are among its successes. Alice & Bob, Aqemia, Vibe, and iBanFirst also feature. This robust history underscores its expertise.
Beyond DTS3, Elaia continues its expansive investment strategy. Earlier this year, in February, Elaia announced the first close of its fifth Digital Venture Fund (DV5). This fund secured €120 million. It aims to scale to €300 million. This demonstrates Elaia's continuous commitment. It invests across various stages and technological domains.
Elaia's network extends across Europe. It maintains offices in Paris, Barcelona, and Tel Aviv. This geographic presence supports its pan-European investment mandate. It fosters strong ties with local ecosystems. The firm operates a joint venture with Lazard, Lazard Elaia Capital. This partnership further supports founders. It provides resources at any stage of their growth.
DTS3 reflects Elaia's unwavering international ambition. It backs founders across the entire European continent. Its growing investor network mirrors this geographic diversity. Elaia is currently in an intense deployment phase. The firm actively seeks ambitious entrepreneurs. These visionaries are building Europe's next generation of deep tech companies. This fund will drive significant innovation. It shapes Europe's technological leadership. It fosters economic growth and solves critical global challenges. Elaia stands ready. It empowers the innovators of tomorrow.